GlassScriptPhysician profile
Michael C Byrd
NPI 1942394663
$59,106.83
in general payments reported to CMS, 2019-2025
17 companies · $13K in 2025
The $13K reported for 2025 was more than what 91% of Otolaryngic Allergy providers received nationally (typical 2025 total: $449).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,351 · 2020: $11K · 2021: $10K · 2022: $11K · 2023: $2,314 · 2024: $1,971 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $2,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,875.00 |
| Food and Beverage | $2,552.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $53,028.76 | 2019-2025 | |
| Medtronic, INC. | $2,968.55 | 2022-2024 | Sinuva, Nuvent |
| Inspire Medical Systems, INC. | $1,761.66 | 2019-2025 | Inspire |
| Glaxosmithkline, LLC. | $296.45 | 2024-2025 | Nucala |
| Stryker Corporation | $241.38 | 2019-2021 | |
| Ars Pharmaceuticals Operations, INC. | $207.58 | 2025 | Neffy |
| Kaleo, INC. | $130.19 | 2022-2023 | Auvi-Q |
| Advanced Bionics, LLC | $117.04 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $79.51 | 2023-2025 | Dupixent |
| Intersect Ent, INC. | $74.01 | 2021 | |
| Genzyme Corporation | $71.93 | 2022-2023 | |
| Hikma Pharmaceuticals USA | $33.30 | 2024-2025 | Ryaltris |
| Lilly USA, LLC | $30.86 | 2025 | Zepbound |
| Astrazeneca Pharmaceuticals LP | $20.68 | 2025 | Tezspire |
| Acclarent, INC | $19.95 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $15.38 | 2023 | Olympus |
| Checkpoint Surgical, INC | $9.60 | 2025 | Checkpoint Stimulators |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.